Announcement
Intuitive Invests.Gp : Investment in BioQ Pharma
RNS Number : 3778M
Intuitive Investments Group plc
21 January 2021
Intuitive Investments Group plc
("IIG" or the "Company")
Investment in BioQ Pharma
Intuitive Investments Group plc (AIM:IIG), a closed-end investment company focussed on the life sciences sector, is pleased to announce its investment of US$1 million by way of unsecured convertible loan notes ("CLNs") in BioQ Pharma Incorporated ("BioQ").
BioQ is a well-established, commercial-stage, medical device and pharmaceutical company, addressing the infusible drugs market. BioQ's proprietary InveniousTM platform comprises a "connect-and-go" drug-device system combination, which can be utilised to improve the delivery of infusible medicines. BioQ's platform includes a bespoke unit-dose delivery solution for infusible drugs, whereby a diluent delivery system and administration line are combined in one self-contained, ready-to-use presentation. The key benefits of the platform include reduced cost and complexity compared to current infusion techniques. Further information on BioQ can be found at the company's website: www.bioqpharma.com .
IIG's investment in BioQ consists of US$1 million of CLNs maturing on 1 November 2021. The terms of the CLN include a coupon of 10% that is accrued and paid on conversion or repayment, warrant coverage, and provisions for conversion into new equity at the time of a qualifying future fundraise (at a 35 per cent. discount to the price of such fundraise) or at maturity.
BioQ is the Company's second investment from its pipeline of opportunities, and follows its successful IPO in December 2020.
David Evans personally invested US$75,000 in Bio Q's Series B funding round in 2009 which is less than an 0.5% interest in the company. Accordingly, David Evans did not vote as a member of the Board of IIG approving the transaction.
In the nine months ended 30 September 2020, BioQ made a net loss of US$5.9million and, as at 30 September 2020, had net liabilities of approximately US$32 million.
David Evans, Chairman of IIG, said:
"We are hugely impressed by BioQ and what Josh Kriesel and the BioQ team have built in the US and Europe. We strongly believe the adoption by the healthcare providers of BioQ's " Pharmacy in a Box" which is also a "connect-and-go" delivery system will continue to accelerate in the near term. Our investment demonstrates IIG's ability to act quickly and opportunistically when compelling opportunities arise."
For further information, please contact:
|
Intuitive Investments Group plc |
|
|
David Evans |
Via Walbrook PR |
|
|
|
|
Strand Hanson Limited - Nominated Adviser |
+44 (0) 20 7409 3494 |
|
James Harris / James Dance / James Bellman |
|
|
|
|
|
Turner Pope Investments (TPI) Ltd - Broker |
+44 (0) 20 3657 0050 |
|
Ben Turner / James Pope / Andrew Thacker |
|
|
|
|
|
Walbrook PR Limited - Media & Investor Relations |
+44 (0)20 7933 8780 or [email protected] |
|
Paul McManus |
+44 (0) 7980 541 893 |
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.
About Intuitive Investments Group plc
The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCDBLFLFFLLBBD
;